| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.29▼ | 0.29▼ | 0.29▼ | 0.31▼ | 0.33▼ |
| MA10 | 0.29▼ | 0.30▼ | 0.30▼ | 0.32▼ | 0.32▼ |
| MA20 | 0.30▼ | 0.30▼ | 0.30▼ | 0.34▼ | 0.50▼ |
| MA50 | 0.30▼ | 0.31▼ | 0.31▼ | 0.36▼ | 0.66▼ |
| MA100 | 0.31▼ | 0.32▼ | 0.33▼ | 0.53▼ | 0.94▼ |
| MA200 | 0.32▼ | 0.33▼ | 0.33▼ | 0.64▼ | 2.00▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▼ | 0.000▼ | -0.001▼ | -0.001▼ | -0.008▼ |
| RSI | 37.016▼ | 35.474▼ | 36.282▼ | 39.108▼ | 32.684▼ |
| STOCH | 27.040 | 7.264▼ | 4.743▼ | 29.294 | 26.706 |
| WILL %R | -92.045▼ | -96.392▼ | -96.392▼ | -96.964▼ | -85.860▼ |
| CCI | -84.421 | -81.424 | -105.191▼ | -131.588▼ | -70.648 |
|
Tuesday, February 17, 2026 05:06 AM
In two non-GLP studies, CUE-401 was well tolerated with no adverse events observedProof-of-concept studies reinforce promising preclinical ...
|
|
Thursday, February 12, 2026 05:41 AM
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the ...
|
|
Friday, December 19, 2025 12:00 AM
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/02/26 | 0.3029 | 0.3029 | 0.288 | 0.2911 | 486,041 |
| 13/02/26 | 0.3001 | 0.3192 | 0.295 | 0.3066 | 352,036 |
| 12/02/26 | 0.35 | 0.35 | 0.30 | 0.30 | 425,503 |
| 11/02/26 | 0.3339 | 0.3499 | 0.3177 | 0.3217 | 306,309 |
| 10/02/26 | 0.3313 | 0.355 | 0.325 | 0.3374 | 768,511 |
| 09/02/26 | 0.318 | 0.33 | 0.305 | 0.3229 | 331,148 |
| 06/02/26 | 0.3146 | 0.327 | 0.3034 | 0.3201 | 379,662 |
| 05/02/26 | 0.3036 | 0.3175 | 0.2901 | 0.3161 | 398,678 |
| 04/02/26 | 0.33 | 0.33 | 0.2921 | 0.3092 | 634,562 |
| 03/02/26 | 0.333 | 0.3397 | 0.3156 | 0.33 | 480,510 |
|
|
||||
|
|
||||
|
|